Accolade Inc.
| NASDAQ: ACCD |
| Healthcare / Healthcare Providers & Services / USA |
| 8.24 | +0.5500 | +7.15% | Vol 2.92M | 1Y Perf -85.50% |
| Jun 24th, 2022 16:00 DELAYED |
| BID | 8.10 | ASK | 8.34 | ||
| Open | 7.69 | Previous Close | 7.69 | ||
| Pre-Market | - | After-Market | 8.33 | ||
| - - | 0.09 1.09% |
| Target Price | 11.60 | Analyst Rating | Moderate Buy 1.92 | |
| Potential % | 40.78 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★★ 55.41 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★+ 49.89 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 7.14 | Earnings Rating | — | |
| Market Cap | 554.50M | Earnings Date | 30th Jun 2022 | |
| Alpha | -0.07 | Standard Deviation | 0.22 | |
| Beta | 2.95 |
Today's Price Range 7.608.24 | 52W Range 4.6155.47 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Neutral |
| Performance | |||
|---|---|---|---|
| 1 Week | - | ||
| 1 Month | - | ||
| 3 Months | -47.95% | ||
| 6 Months | -68.68% | ||
| 1 Year | -85.50% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -31.84 | |||
ROE last 12 Months | -20.20 | |||
ROA (5Y Avg) | -6.44 | |||
ROA last 12 Months | -14.26 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -10.51 | |||
Return on invested Capital Q | -3.03 | |||
Return on invested Capital Y | -15.29 | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | 12.20 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.80 | ||||
| 0.45 | ||||
| 1.54 | ||||
| - | ||||
| -5.60 | ||||
| -0.98 | ||||
| 11.61 | ||||
| 12.72 | ||||
| 340.08M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.50 | ||||
| 3.70 | ||||
| 0.27 | ||||
| 0.37 | ||||
| -43.30 | ||||
| Leverage Ratio | 1.60 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 45.50 | ||||
| -36.50 | ||||
| -24.50 | ||||
| -45.50 | ||||
| -30.72 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 250.49M | ||||
| 3.72 | ||||
| 35.00 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2022 | -0.45 | -0.59 | -31.11 |
| Q03 2022 | -0.68 | -0.65 | 4.41 |
| Q02 2022 | -0.53 | -0.67 | -26.42 |
| Q01 2022 | -0.37 | -0.52 | -40.54 |
| Q04 2021 | -0.12 | -0.13 | -8.33 |
| Q03 2021 | -0.35 | -0.32 | 8.57 |
| Q02 2021 | -0.42 | -0.47 | -11.90 |
| Q01 2021 | - | -1.86 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 30th Jun 2022 |
| Estimated EPS Next Report | -0.73 |
| Estimates Count | 6 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 2.92M |
| Shares Outstanding | 67.29K |
| Shares Float | 64.37M |
| Trades Count | 15.57K |
| Dollar Volume | 23.73M |
| Avg. Volume | 767.23K |
| Avg. Weekly Volume | 526.54K |
| Avg. Monthly Volume | 783.31K |
| Avg. Quarterly Volume | 991.84K |
Accolade Inc. (NASDAQ: ACCD) stock closed at 17.98 per share at the end of the most recent trading day (a -1.86% change compared to the prior day closing price) with a volume of 972.61K shares and market capitalization of 554.50M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Healthcare Providers & Services industry, Healthcare sector and employs 1230 people. Accolade Inc. CEO is Rajeev Singh.
The one-year performance of Accolade Inc. stock is -85.5%, while year-to-date (YTD) performance is -68.74%. ACCD stock has a five-year performance of %. Its 52-week range is between 4.61 and 55.47, which gives ACCD stock a 52-week price range ratio of 7.14%
Accolade Inc. currently has a PE ratio of -2.80, a price-to-book (PB) ratio of 0.45, a price-to-sale (PS) ratio of 1.54, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -14.26%, a ROC of -10.51% and a ROE of -20.20%. The company’s profit margin is -30.72%, its EBITDA margin is -24.50%, and its revenue ttm is $250.49 Million , which makes it $3.72 revenue per share.
Of the last four earnings reports from Accolade Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.73 for the next earnings report. Accolade Inc.’s next earnings report date is 30th Jun 2022.
The consensus rating of Wall Street analysts for Accolade Inc. is Moderate Buy (1.92), with a target price of $11.6, which is +40.78% compared to the current price. The earnings rating for Accolade Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Accolade Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Accolade Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 20.18, ATR14 : 1.29, CCI20 : 158.09, Chaikin Money Flow : 0.02, MACD : 0.01, Money Flow Index : 63.98, ROC : 39.16, RSI : 1.89, STOCH (14,3) : 86.83, STOCH RSI : 0.00, UO : 62.70, Williams %R : -13.17), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Accolade Inc. in the last 12-months were:
Accolade Inc.
Accolade Inc offers technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits. it generates revenue through providing personalized health guidance solutions to members.
CEO: Rajeev Singh
Telephone: +1 206 926-8100
Address: 1201 Third Avenue, Seattle 98101, WA, US
Number of employees: 1 230
TipRanks News for ACCD
Fri, 29 Apr 2022 10:15 GMT Analysts Offer Insights on Technology Companies: Mitek Systems (MITK), Accolade (ACCD) and Argo Blockchain (ARBK)
- TipRanks. All rights reserved.Fri, 14 Jan 2022 12:28 GMT Making Sense of Accolades Risk Factors
- TipRanks. All rights reserved.
